Chinese Academy Of Sciences is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Location: Beijing, China
Type: National Research Academy
Founded: 1949
Affiliation: People's Republic of China
Website: [https://www.cas.cn cas.cn]
The Chinese Academy of Sciences (CAS) is the national academy of the People's Republic of China and the largest national research organization in the world. Founded in 1949, CAS is directly affiliated with the Chinese government and operates over 100 research institutes across China, employing tens of thousands of scientists and researchers.
CAS is at the forefront of global scientific research, with particularly strong programs in neuroscience, molecular biology, genetics, and biotechnology. The academy plays a critical role in advancing understanding of neurodegenerative diseases through its network of specialized institutes focused on brain research, aging, and neurological disorders.
¶ Organization and Structure
CAS comprises:
- Over 100 research institutes across China
- Three universities: University of Science and Technology of China, University of Chinese Academy of Sciences
- Two publishing houses: Science Press, China Scientific Books & Journals
- Over 60,000 researchers and support staff
- Focus: Protein structure, folding, and aggregation
- Key work: Amyloid fibril formation, alpha-synuclein, tau protein
- Focus: Neural development, plasticity, and degeneration
- Key work: Neural circuitry, neurodegeneration mechanisms
- Focus: Primate models of neurodegeneration
- Key work: Non-human primate models for Alzheimer's and Parkinson's disease
¶ Institute of Genetics and Developmental Biology
- Focus: Genetic factors in neurodegeneration
- Key work: Gene editing, genetic risk factors
- Focus: Drug discovery for neurological disorders
- Key work: Small molecule therapeutics, natural products
CAS institutes conduct comprehensive Alzheimer's disease research:
- Amyloid Biology: Understanding Aβ generation, aggregation, and toxicity
- Tau Pathology: Mechanisms of tau phosphorylation and propagation
- Genetic Studies: GWAS in Chinese populations, identification of novel risk genes
- Drug Discovery: Traditional Chinese medicine compounds, small molecule inhibitors
Research programs in Parkinson's disease include:
- Alpha-Synuclein Biology: Aggregation mechanisms, strain diversity
- Mitochondrial Dysfunction: PINK1, Parkin, and mitophagy
- Neuroinflammation: Microglial activation in PD
- Animal Models: Genetic and toxin-based PD models
CAS has extensive research on the biology of aging:
- Cellular Senescence: Mechanisms of neuronal aging
- Telomere Biology: Telomere maintenance in neural stem cells
- Metabolic Changes: Energy metabolism in aging brain
¶ Drug Discovery and Development
CAS plays a major role in neurodegenerative disease drug discovery:
- High-Throughput Screening: Identification of therapeutic compounds
- Natural Products: Screening traditional Chinese medicine for neuroprotective compounds
- Novel Targets: Identification of new therapeutic targets
- Animal Model Development: Transgenic and induced models
- Professor, Institute of Neuroscience, CAS
- Distinguished neuroscientist in neurodegeneration research
- Key focus: Alzheimer's disease mechanisms, synaptic plasticity
- Notable work on APP processing and amyloid generation
- Prof. Yunwu Zhang: Amyloid and tau research
- Prof. Cheng: Parkinson's disease genetics
- Prof. Xia: Neuroinflammation in neurodegeneration
National-level research center for brain science:
- Brain imaging facilities
- Electrophysiology laboratories
- Animal behavior facilities
Focused on understanding mechanisms of brain disorders:
- Alzheimer's disease
- Parkinson's disease
- Stroke
- Depression
Comprehensive neuroscience research:
- Molecular neuroscience
- Systems neuroscience
- Clinical translation
- Super-resolution microscopy
- Electron microscopy
- Live-cell imaging
¶ Genomics and Proteomics Facilities
- Next-generation sequencing
- Mass spectrometry
- Protein crystallography
- Specific pathogen-free (SPF) animal facilities
- Non-human primate facilities
- Zebrafish facilities
CAS collaborates extensively with international partners:
- NIH (USA): Joint research programs
- European Union: Horizon 2020 projects
- Japan RIKEN: Neuroscience partnerships
- UK MRC: Collaborative research
- Nature Publishing Group: Joint journals and conferences
| Disease |
Research Focus |
| Alzheimer's Disease |
Amyloid, tau, biomarkers, drug discovery |
| Parkinson's Disease |
Alpha-synuclein, mitochondria, neuroinflammation |
| ALS |
Genetic modifiers, animal models |
| Huntington's Disease |
Genetic models, therapeutic targets |
| Brain Aging |
Senescence, metabolism, cognition |
CAS offers world-class training:
- Graduate programs (PhD)
- Postdoctoral fellowships
- Visiting scholar programs
- International exchange programs
- Young Investigator programs
- Novel Genetic Risk Factors: GWAS studies identifying new Alzheimer's and Parkinson's risk genes in Chinese populations
- APP Processing: Breakthroughs in understanding amyloid precursor protein metabolism
- Alpha-Synuclein Strains: Characterization of distinct α-synuclein fibril polymorphs
- Traditional Medicine: Discovery of neuroprotective compounds from traditional Chinese medicine
- Non-Human Primate Models: Development of transgenic primate models for neurodegeneration
The study of Chinese Academy Of Sciences has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hardy J, Selkoe DJ. "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science. 2002.
- Spillantini MG, Goedert M. "The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy." Annals of Neurology. 2003.
- Braak H, et al. "Staging of brain pathology related to sporadic Parkinson's disease." Neurobiology of Aging. 2003.
- Selkoe DJ. "Alzheimer's disease: genes, proteins, and therapy." Physiological Reviews. 2001.
- Cookson MR. "The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease." Nature Reviews Neuroscience. 2010.
- Gasser T. "Genetics of Parkinson's disease." Current Opinion in Neurology. 2009.
- Holtzman DM, et al. "Alzheimer's disease: the challenge of the second century." Science Translational Medicine. 2016.
- Querfurth HW, LaFerla FM. "Alzheimer's disease." New England Journal of Medicine. 2010.